Optimization of a novel peptide ligand targeting human carbonic anhydrase IX

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Rana, Shoaib ^a,b   Nissen, Felix ^a   Marr, Annabell ^a,b   Markert, Annette ^a,b   Altmann, Annette ^a,b   Mier, Walter ^a   Debus, Juergen ^a   Haberkorn, Uwe ^a,b   Askoxylakis, Vasileios ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBONATE DEHYDRATASE IX; POLYPEPTIDE; TYROSYLASPARAGINYLTHREONYLASPARAGINYLHISTIDINYLVALYLPROPYLLEUCYLSERYLPROPYLLYSYLTYROSINE; UNCLASSIFIED DRUG; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; LIGAND; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

AMINO ACID ANALYSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CHEMISTRY; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FMOC CHEMISTRY; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; METABOLIC PARAMETERS; METABOLIC STABILITY; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PANCREAS CARCINOMA; PLANAR SCINTIGRAPHY; PROCESS OPTIMIZATION; PROTEIN TARGETING; SCINTIGRAPHY; SERUM; SYNTHESIS; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG DESIGN; GENE EXPRESSION REGULATION; GENETICS; HALF LIFE TIME; METABOLISM; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN TRANSPORT; TUMOR CELL LINE;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BINDING SITES; CARBONIC ANHYDRASES; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HALF-LIFE; HUMANS; ISOTOPE LABELING; LIGANDS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN TRANSPORT;

EID: 84861673417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038279     Document Type: Article

References (25)

1. Hockel M, Vaupel P, (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276.
2. Vaupel P, Mayer A, (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239.
3. Grabmaier K, MC AdW, Verhaegh GW, Schalken JA, Oosterwijk E, (2004) Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23: 5624-5631.
4. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
5. Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, et al. (2008) Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 283: 27799-27809.
6. Choschzick M, Oosterwijk E, Muller V, Woelber L, Simon R, et al. (2011) Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459: 193-200.
7. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083.
8. Potter CP, Harris AL, (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89: 2-7.
9. Supuran CT WJ-Y, (2009) Drug Design of Zinc-Enzyme Inhibitors - Functional, Structural, and Disease Applications; Wang B, editor. Hoboken, New Jersey John Wiley & Sons, Inc.
10. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J, (2007) CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy. Clin Exp Metastasis 24: 149-155.
11. Li G, Bilal I, Gentil-Perret A, Feng G, Zhao A, et al. (2010) CA9 as a molecular marker for differential diagnosis of cystic renal tumors. Urol Oncol.
12. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, et al. (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29: 121-126.
13. Marr A, Markert A, Altmann A, Askoxylakis V, Haberkorn U, (2011) Biotechnology techniques for the development of new tumor specific peptides. Methods 55: 215-222.
14. Askoxylakis V, Garcia-Boy R, Rana S, Kramer S, Hebling U, et al. (2010) A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One 5: e15962.
15. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J, (1992) A novel quasi-viral agent, MaTu, is a two-component system. Virology 187: 620-626.
16. Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, et al. (1993) Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54: 268-274.
17. Liao SY, Brewer C, Zavada J, Pastorek J, Pastorekova S, et al. (1994) Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145: 598-609.
18. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, et al. (1998) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153: 279-285.
19. Thiry A, Dogne JM, Masereel B, Supuran CT, (2006) Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 27: 566-573.
20. Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, et al. (2001) The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Clin Cancer Res 7: 89-92.
21. Tran L, Baars J, Damen C, Beijnen J, Huitema A, (2011) Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab. J Pharm Biomed Anal 56: 609-614.
22. Chrastina A, Zavada J, Parkkila S, Kaluz S, Kaluzova M, et al. (2003) Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 105: 873-881.
23. Li P, Roller PP, (2002) Cyclization strategies in peptide derived drug design. Curr Top Med Chem 2: 325-341.
24. Fischer PM, (2003) The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 4: 339-356.
25. Boy RG, Mier W, Nothelfer EM, Altmann A, Eisenhut M, et al. (2010) Sunflower trypsin inhibitor 1 derivatives as molecular scaffolds for the development of novel peptidic radiopharmaceuticals. Mol Imaging Biol 12: 377-385.